We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zydis

News List

Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement contractpharma
August 11, 2021
Novel formulation of glycopyrrolate will use Catalent’s Zydis ODT delivery technology for adjunctive therapy for the treatment of peptic ulcer.
Catalent, JOS Pharmaceuticals Enter Zydis Formulation Agreement contractpharma
July 14, 2021
Catalent to undertake a feasibility study for the potential development of a CBD product for use as an anesthetic leveraging its ODT technology.
Cybin to Leverage Catalent’s Zydis for Psychiatric Drug contractpharma
March 23, 2021
To apply Zydis orally disintegrating tablet (ODT) technology for delivery of Cybin’s potential therapy for treatment-resistant psychiatric disorders.
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020
Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.